MAP study: RCT of a medication adherence program for patients with type 2 diabetes

Journal of the American Pharmacists Association

Volumn 52, Issue 6, 2012, Pages 753-762

  Odegard, Peggy Soule ^a   Christensen, Dale B ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adherence (medication); Diabetes; Interventions

Indexed keywords

INSULIN; METFORMIN; SULFONYLUREA;

AGED; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHARMACIST; RANDOMIZED CONTROLLED TRIAL; TELECONSULTATION;

EID: 84890036278     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2012.11001     Document Type: Article

References (23)

1. Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ. 2007;33:1014-29.
2. Hertz RP, Unger AN, Lustik AP. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther. 2005;27:1064-73.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-65.
5. Center for Disease Control and Prevention. National diabetes fact sheet, 2007. Accessed at www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf, July 20, 2010.
6. Shane-McWhorter L, Fermo JK, Bultemeier NC, Oderda GM. National survey of pharmacist certified diabetes educators. Pharmacotherapy. 2002;22:1579-93.
7. Rothman RL, Malone R, Bryant B, et al. A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated levels in patients with diabetes. Am J Med. 2005;118:276-84.
8. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med. 2002;162:1149-55.
9. Tsuyuki RT, Olson KL, Dubyk AM, et al. Effect of community pharmacist intervention on cholesterol levels in patients at high risk of cardiovascular events: the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus). Am J Med. 2004;116:130-3.
10. Chabot I, Moisan J, Gregoire JP, Milot A. Pharmacist intervention program for control of hypertension. Ann Pharmacother. 2003;37:1186-93.
11. Maguire TA, McElnay JC, Drummond A. A randomized controlled trial of a smoking cessation intervention based in community pharmacies. Addiction. 2001;96:325-31.
12. Choe HM, Mitrovich S, Dubay D, et al. Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial. Am J Manag Care. 2005;11:253-60.
13. Ragucci KR, Fermo JD, Wessell AM, Chumney EC. Effectiveness of pharmacist-administered diabetes mellitus education and management services. Pharmacotherapy. 2005;25:1809-16.
14. Leal S, Glover JJ, Herrier RN, Felix A. Improving quality of care in diabetes through a comprehensive pharmacist-based disease management program. Diabetes Care. 2004;27:2983-4.
15. Kelly C, Rodgers P. Implementation and evaluation of a pharmacist-managed diabetes service. J Manag Care Pharm. 2000;6:488-93.
16. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003;43:173-84.
17. Garrett DG, Bluml BM. Patient self-management program for diabetes: first-year clinical, humanistic and economic outcomes. J Am Pharm Assoc. 2005;45:130-7.
18. Cranor CW, Christensen DB. The Asheville Project: short-term outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003;43:149-59.
19. Cranor CW, Christensen DB. The Asheville Project: factors associated with outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003;43:160-72.
20. Christensen DB, Hansen RW. Characteristics of pharmacies and pharmacists associated with the provision of cognitive services in the community setting. J Am Pharm Assoc. 1999;39:640-9.
21. Glynn TJ, Manley MW. How to help your patients stop smoking: a National Cancer Institute manual for physicians. Washington, DC: Department of Health & Human Services; 1989.
22. Choudry NK, Shrank WH, Levin RL, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15:457-64.
23. Christensen DB, Williams B, Goldberg HI, et al. Comparison of prescription and medical records in reflecting patient antihypertensive drug therapy. Ann Pharmacother. 1994;28:99-104.